^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iC9-CAR19 cells

    i
    Other names: iC9-CAR19 cells, ATLCAR CD19, ATLCAR.CD19
    Associations

    News

    Trials
    Company:
    Bellicum
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1m
    Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL (clinicaltrials.gov)
    P1/2, N=17, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2040 --> Sep 2037 | Trial primary completion date: Dec 2025 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • iC9-CAR19 cells • rimiducid (AP1903)
    2ms
    Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL (clinicaltrials.gov)
    P1/2, N=17, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=54 --> 17 | Trial completion date: Apr 2041 --> Aug 2040 | Trial primary completion date: Apr 2026 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • iC9-CAR19 cells • rimiducid (AP1903)
    almost4years
    Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL (clinicaltrials.gov)
    P1/2, N=54, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Oct 2036 --> Apr 2041 | Trial primary completion date: Nov 2021 --> Apr 2026
    Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    cyclophosphamide • fludarabine IV • iC9-CAR19 cells • rimiducid (AP1903)